What is LOPJLB’s current signal on IMTX?

LOPJLB’s latest quantitative signal on Immatics N.V. (IMTX) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is IMTX in?

Immatics N.V. (IMTX) is currently classified in the CRISIS HMM market regime on LOPJLB.

LOPJLBMARKETS

SCREENER CHART SD50 CALENDAR NEWS

...

Immatics N.V. (IMTX) Stock · SELL · CRISIS | LOPJLB

Immatics N.V. (IMTX)

Healthcare

$8.69-2.69%Close

SELLCRISIS · day 3

IMTX▼ SELL

$8.69-2.69%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Market cap: $1.2B

Avg volume: 466.5K

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Sector: Healthcare

ANALYST & RATINGS

LOADING…

Loading analyst data…

Company news

globenewswire.com · 7h ago

Immatics Announces $150 Million Underwritten Offering

globenewswire.com · 7d ago

Immatics Announces Second Quarter 2026 Financial Results and Business Update

defenseworld.net · 27d ago

Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80

globenewswire.com · 39d ago

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

globenewswire.com · 39d ago

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

seekingalpha.com · 70d ago

Immatics: PRAME Is Becoming More Than A Single-Asset Story

globenewswire.com · 85d ago

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

globenewswire.com · 85d ago

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

globenewswire.com · 86d ago

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

globenewswire.com · 86d ago

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

globenewswire.com · 87d ago

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Market news & ticker search · RSS for IMTX

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart SD50 News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Plays Feeling Lucky Blog Changelog Docs

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

Terms Privacy

@lopjlb contact@lopjlb.com